Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) refractory to standard regimens

被引：0
|
作者：
Rimassa, L. [1 ,2 ,3 ,4 ]
Sobrero, A. F. [1 ,2 ,3 ,4 ]
Santoro, A. [1 ,2 ,3 ,4 ]
Andretta, V. [1 ,2 ,3 ,4 ]
Gregorc, V. [1 ,2 ,3 ,4 ]
Sclafani, F. [1 ,2 ,3 ,4 ]
Caprioni, F. [1 ,2 ,3 ,4 ]
Caligaris-Cappio, F. [1 ,2 ,3 ,4 ]
Lambiase, A. [1 ,2 ,3 ,4 ]
Bordignon, C. [1 ,2 ,3 ,4 ]
机构：
[1] Inst Clin Humanitas, Rozzano, Italy
[2] Osped San Martino Genova, Genoa, Italy
[3] Ist Sci San Raffaele, Milan, Italy
[4] MolMed, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4088
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients
    Desar, Ingrid M. E.
    van Herpen, Carla M. L.
    van Asten, Jack J. A.
    Fiedler, Walter
    Marreaud, Sandrine
    Timmer-Bonte, Johanna N. H.
    ter Voert, Edwin G. W.
    Lambiase, Antonio
    Bordignon, Claudio
    Heerschap, Arend
    van Laarhoven, Hanneke W. M.
    EUROPEAN JOURNAL OF RADIOLOGY, 2011, 80 (03) : 655 - 661
  • [32] Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)
    van Laarhoven, Hanneke W. M.
    Fiedler, Walter
    Desar, Ingrid M. E.
    van Asten, Jack J. A.
    Marreaud, Sandrine
    Lacombe, Denis
    Govaerts, Anne-Sophie
    Bogaerts, Jan
    Lasch, Peter
    Timmer-Bonte, Johanna N. H.
    Lambiase, Antonio
    Bordignon, Claudio
    Punt, Cornelis J. A.
    Heerschap, Arend
    van Herpen, Carla M. L.
    CLINICAL CANCER RESEARCH, 2010, 16 (04) : 1315 - 1323
  • [33] Phase II study of the clinical and biological activity of cetuximab and celecoxib in patients (pts) with refractory colorectal cancer (CRC)
    Chan, E.
    Merchant, N. B.
    LaFleur, B. J.
    Rothenberg, M. L.
    Coffey, R. J., Jr.
    Morrow, J. D.
    Milne, G. L.
    Trivedi, B. L.
    Lockhart, A. C.
    Berlin, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumours (EORTC 16041)
    Van Herpen, C.
    Fiedler, W.
    Toma, S.
    Marreaud, S.
    Van Laarhoven, H.
    Lasch, P.
    Bogaerts, J.
    Heerschap, A.
    Bordignon, C.
    Punt, C.
    EJC SUPPLEMENTS, 2006, 4 (12): : 113 - 113
  • [35] A phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumors (EORTC 16041)
    Heerschap, A.
    Fiedler, W.
    Marreaud, S.
    van Laarhoven, H.
    Govaerts, A.
    Peters, M.
    Toma, S.
    Bordignon, C.
    Punt, K.
    Van Herpen, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Phase II study of single agent gemcitabine in patients with hormone refractory prostate cancer (HRPC).
    Nilsson, S
    Holmberg, M
    Ljung, G
    Pettersson-Skjold, D
    Blom, R
    Ullén, A
    Westberg, R
    Nilsson, I
    Lennernas, B
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 432S - 432S
  • [37] A biological and pharmacologic phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumors (EORTC 16041).
    Van Herpen, Carla
    Fiedler, Walter
    Marreaud, Sandrine
    Van Laarhoven, Hanneke
    Peters, Marlies
    Govaerts, Anne-Sophie
    Toma, Salvatore
    Bordignon, Claudio
    Heerschap, Arend
    Punt, Kees
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3457S - 3457S
  • [38] Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC).
    Sawyer, M. B.
    Iqbal, S.
    Lenz, H.
    Lima, C. S. Rocha
    Rossignol, D. P.
    Krivelevich, I.
    Fan, J.
    El-Khoueiry, A. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] NON-RANDOMIZED PHASE II STUDY COMPARING METRONOMIC REGIMENS OF CHEMOTHERAPY IN PATIENTS (PTS) WITH REFRACTORY METASTATIC COLORECTAL CANCER (MCRC)
    Chubenko, V. A.
    Protsenko, S. A.
    Mikhalychenko, T. D.
    Moiseyenko, F. V.
    Brezhnev, N. V.
    Novik, A. V.
    Volkov, N. M.
    Semenov, I. I.
    Moiseyenko, V. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 181 - 182
  • [40] A phase I safety and IRK study of the novel vascular targeting agent (VTA), Exherin, in patients with refractory solid tumors stratified according to N-cadherin expression
    Jonker, DJ
    Avruch, L
    Stewart, DJ
    Goel, R
    Goss, G
    Dent, S
    Reaume, MN
    Spencer, TA
    Peters, WP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 214S - 214S
12345